Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Alcohol kills – and in this case, that could be a good thing.
Medtronic decides that Solitaire is best played with a partner.